Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Related studies linked through entity extraction aliases.